^"Second-quarter 2008 results"(PDF). Press Release. Sanofi-Aventis. 2008-07-31. Archived from the original(PDF) on 2008-12-06. Retrieved 2009-06-10. It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).